KM Research Hub
← 返回论文库
无 KM 图 入排:排除 图源:可得 入排置信度 0.98

Vonoprazan-based quadruple therapy is non-inferior to esomeprazole-based quadruple therapy for Helicobacter pylori eradication: A multicenter, double-blind, randomized, phase 3 study.

Zhiqiang Song, Qin Du, Guoxin Zhang, Zhenyu Zhang, Fei Liu, Nonghua Lu, Liqun Gu, Shingo Kuroda, Liya Zhou

Chin Med J (Engl) 138(22) 2938-2946

PMID39965795
PMCIDPMC12634238
DOI10.1097/CM9.0000000000003437
发表日期2025-02-18
入排依据:未发现恶性肿瘤人群证据。
已检查 3 张 PubMed Figure,均未识别为 KM 图:Figure 1:研究设计图;Figure 2:AI 判定为 flow diagram;Figure 3:AI 判定为 other。
摘要

摘要

BACKGROUND: Owing to the high prevalence of antibiotic resistance in Helicobacter pylori ( H. pylori ) in China, bismuth-containing quadruple therapies have been recommended for H. pylori eradication. This study compared the efficacy and safety of quadruple regimens containing vonoprazan vs . esomeprazole for H. pylori eradication in a patient population in China. METHODS: This was a phase 3, multicenter, randomized, double-blind study. Patients with confirmed H. pylori infection were randomized 1:1 to receive quadruple therapy for 14 days: amoxicillin 1000 mg and clarithromycin 500 mg after meals, bismuth potassium citrate 600 mg before meals, plus either vonoprazan 20 mg or esomeprazole 20 mg before meals, all twice daily. The primary outcome was the eradication rate of H. pylori , evaluated using a 13 C urea breath test at 4 weeks after treatment. The non-inferiority margin was at 10%. RESULTS: The study included 510 patients, 506 of whom completed the follow-up assessment. The primary analysis revealed eradication rates of 86.8% (210/242) and 86.7% (208/240) for vonoprazan and esomeprazole therapy, respectively (treatment difference: 0.1%; 95% confidence interval [CI]: -5.95, 6.17; non-inferiority P = 0.0009). Per-protocol analysis showed eradication rates of 87.4% for vonoprazan and 86.3% for esomeprazole (treatment difference: 1.2%; 95% CI: -5.03, 7.36; non-inferiority P = 0.0004). Vonoprazan and esomeprazole were well tolerated, with similar safety profiles. CONCLUSION: Vonoprazan was found to be well-tolerated and non-inferior to esomeprazole for eradicating H. pylori in patients from China. TRIAL REGISTRATION: ClinicalTrials.gov , NCT04198363.

KM 提取结果

0 个 Figure · 0 个 KM 面板

尚未提取到 KM 面板。
其他 Figure(3,默认折叠)

这些图片未产生 KM 曲线结果,不在主页面重复展示。

Figure 1Figure 1 Overview of the phase 3, multicenter, randomized, double-blind study design to compare the efficacy and safety of quadruple regimens containing vonoprazan vs . esomeprazole for HP eradication. 13 C-UBT: Carbon-13 urea breath test; b.i.d: Twice daily; HP: Helicobacter pylori ; HP+: HP positive.
非 KM Figure
Figure 2Figure 2 Flow chart of patient disposition in this study comparing the efficacy and safety of quadruple regimens containing vonoprazan vs . esomeprazole for HP eradication. * Two patients were not randomized as the quota for enrolment was full. It was not classified into any of the prespecified reasons, including AE, PD, lost to follow up, voluntary withdrawal by participant, meeting exclusion criteria, and not meeting inclusion criteria, etc. † 28–35 days after the last dose. AE: Adverse event; HP: Helicobacter pylori ; PD: Protocol deviation; PP: Per protocol; UBT: Urea breath test.
非 KM Figure
Figure 3Figure 3 The H. pylori eradication rates with vonoprazan therapy and esomeprazole therapy. The P -values for the non-inferiority of vonoprazan therapy compared with esomeprazole therapy are provided. The differences in the eradication rates between these two therapies (vonoprazan vs . esomeprazole) were 0.1% (95% Wald CI: −5.95, 6.17) in the full analysis set and 1.2% (95% Wald CI: −5.03, 7.36) in the per-protocol analysis. CI: Confidence interval; H. pylori : Helicobacter pylori .
非 KM Figure